Authors: Kyu Sik Jung Jun Yong Park Young Eun Chon HyonSuk Kim Wonseok Kang Beom Kyung Kim Seung Up Kim Do Young Kim KwangHyub Han Sang Hoon Ahn
Publish Date: 2015/12/19
Volume: 51, Issue: 8, Pages: 830-839
Abstract
A total of 113 consecutive patients with CHB 45 HBeAgpositive and 68 HBeAgnegative CHB patients who met the cessation criteria of NA treatment as per the AsianPacific Association for the Study of the Liver APASL guideline were enrolled in this prospective cohort study The primary endpoint was to evaluate virological relapse VR rate within 1 year which was defined as reappearance of hepatitis B virus HBV–DNA 2000 IU/mL after cessation of NA treatment In this cohort entecavir was used in 81 717 and lamivudine in 32 283 patientsWithin 1 year after NA treatment VR occurred in 26 578 HBeAgpositive patients and in 37 544 HBeAgnegative patients In univariate and subsequent multivariate analysis age 40 years odds ratio OR 10959 95 confidence interval CI 2211–54320 P = 0003 and a pretreatment HBV DNA level 2000000 IU/mL OR 9285 95 CI 1545–55795 P = 0036 were identified as independent risk factors for VR in HBeAgpositive patients and age 40 years OR 6690 95 CI 1314–34057 P = 0022 and an endoftreatment HBcrAg level 37 log IU/mL OR 3751 95 CI 1187–11856 P = 0024 were identified in HBeAgnegative patients During follow up neither hepatic decompensation nor hepatocellular carcinoma HCC occurred and HBV DNA suppression was achieved in all patients who received antiviral retreatmentOur data suggested that the APASL stopping rule could be applied if a candidate was properly selected using individual risk factors However regular monitoring should be performed after cessation of NA treatment and longterm outcomes need to be evaluated further
Keywords: